JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Original Article
Assessment of anesthesia residents' awareness and knowledge levels regarding malignant hyperthermia in relation to their residency
Aims: Malignant hyperthermia (MH) is an uncommon but life-threatening anesthetic emergency that necessitates prompt diagnosis and swift care. It is imperative for patient safety that anesthesia assistants, identify both the early and late manifestations of MH. This study sought to assess the knowledge and awareness of anesthesiology assistants concerning MH. Methods: This cross-sectional study encompassed 215 anesthesia residents. The knowledge level of MH was evaluated by a total knowledge score derived from replies to questions 6–24 of the questionnaire. The knowledge level was categorized as low, moderate, and high. Results: The participants' average knowledge score was 12.50±3.19, with 19.1% exhibiting low knowledge, 53.0% demonstrating medium knowledge, and 27.9% possessing high knowledge. Knowledge scores shown a substantial increase with the prolongation of residence length (Kruskal–Wallis H=26.34, p


1. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet. 1960;276(7140):45-46.
2. Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133-140. doi: 10.1016/j.bja.2020.04.089
3. Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi:10.1186/s13023-015-0310-1
4. Glahn KPE, Girard T, Hellblom A, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025;134(1): 221-223, doi:10.1016/j.bja.2024.09.022
5. Schneiderbanger D, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355-362. doi:10.2147/tcrm.S47632
6. Group EMH. European Malignant Hyperthermia Group. 2015. Available from: http://www.emhg.org [Last Accessed; 10 July 2015].
7. Wolvetang T, Hofland J, Takkenberg H. Knowledge on malignant hyperthermia: as rare as the disease? A nation wide survey. BMC Anesthesiol. 2014;14(1):A18. doi:10.1186/1471-2253-14-S1-A18
8. Monzani R, Alampi D, Bignami E, et al. National insights on malignant hyperthermia: a SIAARTI survey on clinical practices, preparedness, and future directions. J Anesth Analg Crit Care. 2025;5(1):85. doi:10.1186/s44158-025-00293-4
9. Wang J, Yu Y, Gao Y, et al. The anesthesiologists' perception of malignant hyperthermia and availability of dantrolene in China: a cross-sectional survey. Risk Manag Healthc Policy. 2024;17:763-773. doi:10.2147/rmhp.S454895
10. Tan L, Yu H, Yan J, et al. The knowledge profile, competence and pending problems of Chinese anesthesiologists in dealing with malignant hyperthermia: a cross-sectional survey. J Multidiscip Healthc. 2023;16: 133-142. doi:10.2147/jmdh.S387025
11. Larach MG, Brandom BW, Allen GC, et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119(6):1359-1366. doi:10.1213/ane.0000000000000421
12. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth. 2000;85(1):118-128. doi:10.1093/bja/85.1.118
13. Glahn KPE, Girard T, Hellblom A, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025;134(1): 221-223. doi:10.1016/j.bja.2024.09.022
Volume 7, Issue 2, 2026
Page : 330-335
_Footer